Related Experiment Videos
Risperidone-associated hyperprolactinemia
A E Kearns1, D C Goff, D L Hayden
1Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Summary
Risperidone significantly increases prolactin levels in schizophrenia patients more than clozapine or typical antipsychotics. This hyperprolactinemia can negatively impact patient health and treatment adherence.
Area of Science:
- Psychiatry
- Endocrinology
- Pharmacology
Background:
- Antipsychotic medications are crucial for managing schizophrenia.
- Hyperprolactinemia is a known side effect of some antipsychotics.
- Understanding comparative prolactin-inducing effects is vital for patient care.
Purpose of the Study:
- To compare the prolactin-elevating effects of risperidone, clozapine, and typical antipsychotics.
- To assess these effects in an outpatient, community-based psychiatric population.
Main Methods:
- Measured prolactin and thyroid-stimulating hormone (TSH) levels.
- Studied 68 outpatients with schizophrenia on antipsychotic medications.
- Recruited participants from a community mental health clinic.
Main Results:
- Risperidone caused significantly higher prolactin levels in both women (100%) and men (94%) compared to clozapine and typical antipsychotics.
- No significant differences in TSH concentrations were observed between medication groups.
- In the risperidone group, prolactin levels were higher in women than men and inversely related to age.
Conclusions:
- Risperidone is a potent inducer of hyperprolactinemia in outpatients with schizophrenia.
- The elevated prolactin levels associated with risperidone may negatively affect patient health and compliance.
- Further research into managing risperidone-induced hyperprolactinemia is warranted.